Clearance of S-(3-amino-2-hydroxypropyl) phosphorothioate (WR-77913) in rats

Tim T. Lam, David Liu, Michael A. Brody, Ralph Chu, Mark O.M. Tso

Research output: Contribution to journalArticlepeer-review

Abstract

Complications of radiotherapy in the treatment of retinal and choroidal neoplastic diseases include cataract formation, radiation retinopathy, neovascular glaucoma, cystoid macular edema, and subretinal neovascularization. These side effects may be minimized by the use of compounds known to have a protective effect on normal ocular tissues without impeding the benefits of therapy. Phosphorothioates, first developed under the Antiradiation Drug Development Program of the U.S. Army Medical Research and Development Command, have been reported to protect normal tissues during radiation therapy in a variety of animal models. One of the phosphorothioates, WR-77913 (S-[3-amino-2-hydroxylpropyl] phosphorothioate) was found to inhibit cataract formation in rats after radiation exposure. To test the efficacy of WR-77913 in the retina, we established a high-pressure liquid chromatography method to measure the levels of dephosphorylated WR-77913 and studied the drug's clearance from the lens, retina, blood, kidney, and liver in rats.

Original languageEnglish (US)
Pages (from-to)661-667
Number of pages7
JournalExperimental eye research
Volume52
Issue number6
DOIs
StatePublished - Jun 1991
Externally publishedYes

Keywords

  • WR-77913
  • clearance
  • phosphorothioate
  • radioprotector
  • radiotherapy

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Fingerprint Dive into the research topics of 'Clearance of S-(3-amino-2-hydroxypropyl) phosphorothioate (WR-77913) in rats'. Together they form a unique fingerprint.

Cite this